share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/10/24 15:18

Moomoo AI 已提取核心訊息

Titan Pharmaceuticals announced that Dato' Seow Gim Shen has resigned from his positions as Chief Executive Officer and Chairman of the Board on October 24, 2024. Mr. Shen cited personal reasons for his departure, emphasizing that his decision was not due to any disagreements with the Board or company management regarding operations, policies, or practices.The company has initiated a search for a suitable replacement for Mr. Shen. The management affirmed that his resignation is not expected to affect the previously announced business combination with KE Sdn. Bhd., which continues to be pursued by the company.
Titan Pharmaceuticals announced that Dato' Seow Gim Shen has resigned from his positions as Chief Executive Officer and Chairman of the Board on October 24, 2024. Mr. Shen cited personal reasons for his departure, emphasizing that his decision was not due to any disagreements with the Board or company management regarding operations, policies, or practices.The company has initiated a search for a suitable replacement for Mr. Shen. The management affirmed that his resignation is not expected to affect the previously announced business combination with KE Sdn. Bhd., which continues to be pursued by the company.
泰坦製藥宣佈,邵金生(Dato' Seow Gim Shen)已於2024年10月24日辭去首席執行官和董事會主席職務。邵先生因個人原因辭職,強調他的決定並非因與董事會或公司管理層在運營、政策或實踐上的任何分歧。公司已開始尋找邵先生的合適接替人選。管理層確認,他的辭職預計不會影響先前宣佈的與KE Sdn. Bhd.的業務合併,該合併仍在公司追求之中。
泰坦製藥宣佈,邵金生(Dato' Seow Gim Shen)已於2024年10月24日辭去首席執行官和董事會主席職務。邵先生因個人原因辭職,強調他的決定並非因與董事會或公司管理層在運營、政策或實踐上的任何分歧。公司已開始尋找邵先生的合適接替人選。管理層確認,他的辭職預計不會影響先前宣佈的與KE Sdn. Bhd.的業務合併,該合併仍在公司追求之中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息